Latest Medical Devices News

Cochlear Limited has extended its on-market share buy-back program, allowing the company to repurchase up to AUD 75 million of its fully paid ordinary shares until August 2026.

Cochlear Limited reported a solid FY25 with 4% revenue growth and a 1% rise in underlying profit, underpinned by new product launches and expanding evidence linking implants to reduced dementia risk. The company’s FY26 outlook signals further gains as it advances market leadership and innovation.

Cochlear Limited reported a 4% revenue rise in FY25, driven by strong implant sales and launched the world’s first smart cochlear implant system. The company forecasts up to 17% profit growth in FY26, underpinned by innovation and expanding markets.

Cochlear Limited has announced a fully franked ordinary dividend of AUD 2.15 per share for the six months ending June 2025, payable in October with multi-currency options for shareholders.

Cochlear Limited has reported steady financial growth with a 4% rise in sales revenue and a 9% increase in underlying net profit for the fiscal year ending June 2025, maintaining its dividend payout.

Atomo Diagnostics has successfully placed $416,611.77 from its Share Purchase Plan shortfall, bolstered by a recent US order from Lumos Diagnostics. This capital injection strengthens Atomo’s position as it scales up production of its Pascal cassettes.

EBR Systems has secured FDA approval for its pioneering leadless WiSE CRT System and obtained key Medicare reimbursement endorsements, setting the stage for its commercial rollout. The company also completed a significant capital raise to support its market expansion.

Anteris Technologies reported solid clinical progress with 130 patients implanted with its DurAVR heart valve and is gearing up for its pivotal PARADIGM trial with 79 qualified sites worldwide. The company also strengthened its leadership with two new board members amid ongoing FDA engagement.

Anteris Technologies Global Corp. reported a $42.7 million net loss for the first half of 2025 amid advancing preparations for its pivotal DurAVR Transcatheter Heart Valve trial. The company’s recent IPO proceeds are fueling R&D and manufacturing scale-up as it targets regulatory approvals.

Avita Medical reported an 18% revenue increase and a 30% reduction in net loss for the first half of 2025, signaling progress as it scales commercial operations and targets profitability by 2026.

AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.

AVITA Medical’s Q2 2025 update reveals a temporary setback in RECELL demand due to Medicare reimbursement delays, offset by strong revenue growth and promising clinical data. The company anticipates recovery and renewed growth in the second half of the year.